(HealthDay News) — New research supports the recent US recommendation for 2, rather than 3, doses of the human papillomavirus (HPV) vaccine to protect against genital warts in preteens and teens. The report was published in Sexually Transmitted Diseases.
The new study assessed the prevalence of warts among 387,906 girls. The researchers determined whether they’d been vaccinated against HPV, and if so, how many doses they had received.
Beyond the conclusion that 2 doses were just as protective as 3, the researchers found that both dose regimens offered much more protection against genital warts than a single dose or no vaccine at all.
“This study validates the new recommendations, and allows us to confidently move forward with the 2-dose schedule for the prevention of genital warts,” lead author Rebecca Perkins, MD, of the Boston University Medical Center, said in a center news release.
- Perkins RB, Lin M, Wallington SF, Hanchate A. Impact of number of human papillomavirus vaccine doses on genital warts diagnoses among a national cohort of US adolescents. Sex Transm Dis. 2017. doi:10.1097/OLQ.0000000000000615